Kairos Pharma, LTD 8-K filings

Kairos Pharma and Bayer are collaborating to investigate the combination of ENV-105 and XOFIGO for metastatic prostate cancer.

Kairos Pharma announced compelling interim safety data from its Phase 1 trial of ENV-105 in combination with osimertinib for advanced EGFR-mutated lung cancer patients, showing zero Grade 3+ toxicities.

Kairos Pharma Ltd. announced the results of its 2026 annual meeting of stockholders, where shareholders approved director elections, auditor ratification, a reverse stock split, executive compensation, and amendments to the equity incentive plan.

Kairos Pharma provides a mid-year update, detailing a strategic asset acquisition and outlining key milestones for the remainder of 2026, including clinical trial initiations and data readouts.

Kairos Pharma, Ltd. presented an investor presentation at the 2026 LD Micro Invitational XVI, providing updates on its clinical program and partnering activities.

Kairos Pharma, Ltd. has entered into a binding term sheet to acquire worldwide rights to CL-273, an AI-designed pan-EGFR inhibitor for lung cancer, from Celyn Therapeutics, Inc.

Kairos Pharma signs a term sheet to acquire worldwide rights to two clinical-stage oncology assets, CL-273 and CL-741, from Celyn Therapeutics to target non-small cell lung cancer.

Kairos Pharma's Compensation Committee approved $950,000 in restricted stock units and $227,500 in cash bonuses for executive officers and directors for their service.

Kairos Pharma, Ltd. announced the novation of key exclusive license agreements and will present encouraging preliminary Phase 2 data for its prostate cancer therapeutic at the ESMO Congress.

Kairos Pharma announced positive interim efficacy data from its Phase 2 clinical trial of ENV105 in metastatic castration-resistant prostate cancer, showing a median progression-free survival of over 13 months.

Kairos Pharma announced a virtual KOL event to discuss interim efficacy results from its Phase 2 trial of ENV105 for advanced prostate cancer.

Kairos Pharma announced it will present initial Phase 1 data for its lead candidate ENV105 in non-small cell lung cancer at the World Lung Cancer Conference.

Kairos Pharma, Ltd. announced positive interim safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) for metastatic castration-resistant prostate cancer, showing the drug was well tolerated with no Grade 3 or 4 toxicities.

Kairos Pharma, Ltd. announced the engagement of Barretto Pacific Corporation for investor relations services and reported the results of its annual stockholders' meeting, where all director nominees were elected and a significant authorization for future share issuance below minimum price was approved.

Kairos Pharma, Ltd. announced positive new data on its investigational small molecule GITR ligand agonist KROS101, highlighting its potential as a cancer immunotherapy at the ASCO 2025 Annual Meeting.

Kairos Pharma, Ltd. has replaced Marcum LLP with Weinberg and Company, P.A. as its independent registered public accounting firm, effective April 23, 2025.

Kairos Pharma's CEO updated stockholders on the progress of ENV105 clinical trials for prostate and lung cancer, along with the company's business plans for the year.

Kairos Pharma announces a peer-reviewed publication highlighting a potential breakthrough in addressing drug resistance to EGFR-targeted therapies for non-small cell lung cancer (NSCLC) patients.

Kairos Pharma announced positive preclinical data for its investigational compounds KROS 101 and KROS 401, suggesting potential as therapeutics for melanoma and glioblastoma.

Kairos Pharma presented preclinical data on its GITR agonist, KROS101, at the AACR-JCA Joint Conference, showcasing its potential as a therapeutic for melanoma and glioblastoma.

Kairos Pharma, Ltd. has completed a private placement of securities, raising $3.5 million through the sale of units consisting of pre-funded warrants and common stock purchase warrants.

Kairos Pharma, Ltd. has entered into a securities purchase agreement to raise $3.5 million through the sale of common and pre-funded units, including warrants.

Kairos Pharma, Ltd. has appointed Dr. Rahul Singhvi to its board of directors, effective immediately, following the resignation of Dr. Rosemary Mazanet.

Kairos Pharma will dual list its shares on the Upstream exchange, a global securities trading app, starting November 26, 2024, to broaden its investor base and enhance liquidity.

Kairos Pharma's CEO, Dr. John S. Yu, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, and the company has updated its investor presentation.

Kairos Pharma has entered into a consulting agreement with Cross Current Capital for financial and business advisory services, including a cash payment of $200,000 and $500,000 in restricted stock.

Kairos Pharma has entered into agreements with CEO.CA Technologies for internet-based financial communications and with Belair Capital Advisors for strategic advisory services.

Kairos Pharma has entered into an agreement with PreCheck Health Services to develop biomarkers for their cancer therapy, ENV105, aimed at improving patient selection and treatment monitoring in lung and prostate cancer clinical trials.

Kairos Pharma, a clinical-stage biopharmaceutical company, has successfully completed its initial public offering, raising $6.2 million before expenses.